Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $2.2 million.

  • Cartesian Therapeutics' Accounts Payables rose 33036.75% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 33036.75%. This contributed to the annual value of $288000.0 for FY2024, which is 9085.71% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Accounts Payables stood at $2.2 million for Q3 2025, which was up 33036.75% from $454000.0 recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Accounts Payables ranged from a high of $3.2 million in Q4 2023 and a low of $154000.0 during Q2 2021
  • In the last 5 years, Cartesian Therapeutics' Accounts Payables had a median value of $517000.0 in 2024 and averaged $1.0 million.
  • Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Accounts Payables was 97191.01% (2024), while the steepest drop was 9085.71% (2024).
  • Cartesian Therapeutics' Accounts Payables (Quarter) stood at $224000.0 in 2021, then skyrocketed by 41.07% to $316000.0 in 2022, then soared by 896.84% to $3.2 million in 2023, then tumbled by 90.86% to $288000.0 in 2024, then surged by 672.57% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $454000.0 for Q2 2025, and $2.1 million during Q1 2025.